View ValuationMedpace Holdings 향후 성장Future 기준 점검 3/6Medpace Holdings (는) 각각 연간 9.4% 및 7.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 8.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 32.9% 로 예상됩니다.핵심 정보9.4%이익 성장률8.72%EPS 성장률Life Sciences 이익 성장20.5%매출 성장률7.6%향후 자기자본이익률32.86%애널리스트 커버리지Good마지막 업데이트08 Jul 2026최근 향후 성장 업데이트공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.공시 • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.공시 • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.공시 • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €467, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €547 per share.New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.공시 • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026공시 • Jun 06Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships.Board Change • Apr 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.Buy Or Sell Opportunity • Mar 27Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to €385. The fair value is estimated to be €496, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.공시 • Mar 25Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026공시 • Mar 17Medpace Holdings, Inc., Annual General Meeting, May 15, 2026Medpace Holdings, Inc., Annual General Meeting, May 15, 2026.Buy Or Sell Opportunity • Mar 12Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to €376. The fair value is estimated to be €493, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.Buy Or Sell Opportunity • Feb 12Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to €328. The fair value is estimated to be €453, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period.Board Change • Feb 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Jan 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to €473. The fair value is estimated to be €598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.공시 • Jan 06Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Significant insider selling over the past 3 months (€62m sold).Recent Insider Transactions • Nov 13Executive Vice President of Operations recently sold €9.4m worth of stockOn the 11th of November, Susan Burwig sold around 18k shares on-market at roughly €522 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €17m.Recent Insider Transactions • Oct 30Executive Vice President of Operations recently sold €1.0m worth of stockOn the 27th of October, Susan Burwig sold around 2k shares on-market at roughly €520 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €8.1m.Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: US$3.95 (vs US$3.11 in 3Q 2024)Third quarter 2025 results: EPS: US$3.95 (up from US$3.11 in 3Q 2024). Revenue: US$659.9m (up 24% from 3Q 2024). Net income: US$111.1m (up 15% from 3Q 2024). Profit margin: 17% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.공시 • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.Buy Or Sell Opportunity • Oct 10Now 20% undervaluedOver the last 90 days, the stock has risen 59% to €436. The fair value is estimated to be €547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.7% per annum. Earnings are also forecast to grow by 8.1% per annum over the same time period.공시 • Sep 24Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025Recent Insider Transactions • Sep 04Chairman & CEO recently sold €15m worth of stockOn the 2nd of September, August Troendle sold around 37k shares on-market at roughly €408 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €19m. August has been a net seller over the last 12 months, reducing personal holdings by €34m.Recent Insider Transactions • Aug 22Independent Director recently sold €662k worth of stockOn the 19th of August, Cornelius McCarthy sold around 2k shares on-market at roughly €398 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €19m. Insiders have been net sellers, collectively disposing of €24m more than they bought in the last 12 months.Recent Insider Transactions • Jul 30Chairman & CEO recently sold €19m worth of stockOn the 28th of July, August Troendle sold around 48k shares on-market at roughly €389 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was August's only on-market trade for the last 12 months.Reported Earnings • Jul 23Second quarter 2025 earnings released: EPS: US$3.16 (vs US$2.85 in 2Q 2024)Second quarter 2025 results: EPS: US$3.16 (up from US$2.85 in 2Q 2024). Revenue: US$603.3m (up 14% from 2Q 2024). Net income: US$90.3m (up 2.2% from 2Q 2024). Profit margin: 15% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.공시 • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.공시 • Jun 24Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025이익 및 매출 성장 예측BIT:1MEDP - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20283,258602743796912/31/20272,9495406296741212/31/20262,774493569613123/31/20262,678460711739N/A12/31/20252,530451682713N/A9/30/20252,358433677711N/A6/30/20252,232418580614N/A3/31/20252,157416541582N/A12/31/20242,109404572609N/A9/30/20242,071366536575N/A6/30/20242,030340503540N/A3/31/20241,963312473506N/A12/31/20231,886283397433N/A9/30/20231,782273378414N/A6/30/20231,673268373408N/A3/31/20231,563257385422N/A12/31/20221,460245351388N/A9/30/20221,374227286322N/A6/30/20221,286209250286N/A3/31/20221,213199221252N/A12/31/20211,142181235263N/A9/30/20211,094182271298N/A6/30/20211,028175256285N/A3/31/2021955159235267N/A12/31/2020926145227259N/A9/30/2020896124181210N/A6/30/2020882107188215N/A3/31/2020891110196217N/A12/31/2019861100N/A202N/A9/30/201982393N/A184N/A6/30/201978688N/A173N/A3/31/201974278N/A167N/A12/31/201870573N/A157N/A9/30/201861261N/A146N/A6/30/201853152N/A132N/A3/31/201845645N/A121N/A12/31/201738639N/A97N/A9/30/201738228N/A98N/A6/30/201737923N/A101N/A3/31/201737718N/A78N/A12/31/201637113N/A92N/A9/30/20163615N/A91N/A6/30/20163480N/A80N/A3/31/2016332-5N/A94N/A12/31/2015320-9N/A86N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 1MEDP 의 연간 예상 수익 증가율(9.4%)이 saving rate(3.3%)보다 높습니다.수익 vs 시장: 1MEDP 의 연간 수익(9.4%)이 Italian 시장(10.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 1MEDP 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 1MEDP 의 수익(연간 7.6%)이 Italian 시장(연간 5.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 1MEDP 의 수익(연간 7.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 1MEDP의 자본 수익률은 3년 후 32.9%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/10 10:42종가2026/07/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medpace Holdings, Inc.는 20명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Eric ColdwellBairdLuke SergottBarclaysSean DodgeBMO Capital Markets Equity Research17명의 분석가 더 보기
공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.
공시 • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.
공시 • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.
공시 • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.
Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €467, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €547 per share.
New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
공시 • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026
공시 • Jun 06Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships.
Board Change • Apr 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.
Buy Or Sell Opportunity • Mar 27Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to €385. The fair value is estimated to be €496, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.
공시 • Mar 25Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026
공시 • Mar 17Medpace Holdings, Inc., Annual General Meeting, May 15, 2026Medpace Holdings, Inc., Annual General Meeting, May 15, 2026.
Buy Or Sell Opportunity • Mar 12Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to €376. The fair value is estimated to be €493, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.
Buy Or Sell Opportunity • Feb 12Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to €328. The fair value is estimated to be €453, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period.
Board Change • Feb 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.
Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Jan 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to €473. The fair value is estimated to be €598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.
공시 • Jan 06Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Significant insider selling over the past 3 months (€62m sold).
Recent Insider Transactions • Nov 13Executive Vice President of Operations recently sold €9.4m worth of stockOn the 11th of November, Susan Burwig sold around 18k shares on-market at roughly €522 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €17m.
Recent Insider Transactions • Oct 30Executive Vice President of Operations recently sold €1.0m worth of stockOn the 27th of October, Susan Burwig sold around 2k shares on-market at roughly €520 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €8.1m.
Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: US$3.95 (vs US$3.11 in 3Q 2024)Third quarter 2025 results: EPS: US$3.95 (up from US$3.11 in 3Q 2024). Revenue: US$659.9m (up 24% from 3Q 2024). Net income: US$111.1m (up 15% from 3Q 2024). Profit margin: 17% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
공시 • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.
Buy Or Sell Opportunity • Oct 10Now 20% undervaluedOver the last 90 days, the stock has risen 59% to €436. The fair value is estimated to be €547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.7% per annum. Earnings are also forecast to grow by 8.1% per annum over the same time period.
공시 • Sep 24Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
Recent Insider Transactions • Sep 04Chairman & CEO recently sold €15m worth of stockOn the 2nd of September, August Troendle sold around 37k shares on-market at roughly €408 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €19m. August has been a net seller over the last 12 months, reducing personal holdings by €34m.
Recent Insider Transactions • Aug 22Independent Director recently sold €662k worth of stockOn the 19th of August, Cornelius McCarthy sold around 2k shares on-market at roughly €398 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €19m. Insiders have been net sellers, collectively disposing of €24m more than they bought in the last 12 months.
Recent Insider Transactions • Jul 30Chairman & CEO recently sold €19m worth of stockOn the 28th of July, August Troendle sold around 48k shares on-market at roughly €389 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was August's only on-market trade for the last 12 months.
Reported Earnings • Jul 23Second quarter 2025 earnings released: EPS: US$3.16 (vs US$2.85 in 2Q 2024)Second quarter 2025 results: EPS: US$3.16 (up from US$2.85 in 2Q 2024). Revenue: US$603.3m (up 14% from 2Q 2024). Net income: US$90.3m (up 2.2% from 2Q 2024). Profit margin: 15% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
공시 • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.
공시 • Jun 24Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025